Opening book details…
Can I read Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis on EtoBox?
Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis by Heejung Chae; Hyehyun Jeong; Jaekyung Cheon; Hong Jae Chon; Hyewon Ryu; Il-Hwan Kim; Myoung Joo Kang; Jae Ho Jeong; Baek-Yeol Ryoo; Kyu-pyo Kim; Changhoon Yoo is a Medicine article available to read on EtoBox.
What is Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis about?
## Background: FOLFIRINOX (fluorouracil, folinic acid, irinotecan plus oxaliplatin) is an effective standard first-line treatment option for advanced pancreatic ductal adenocarcinoma (PDAC). There is no clear consensus on the second-line treatment following progression on FOLFIRINOX. In this multicenter retrospective analysis, we evaluated the efficacy and tolerability of second-line nab-P/Gem (nab-paclitaxel and gemcitabine) after progression on FOLFIRNOX in PDAC. ## Methods: Patients with unresectable or metastatic PDAC who received nab-P/Gem after progression on FOLFIRINOX between February 2016 and February 2019 were identified from five referral cancer centers in South Korea. Baseline characteristics, treatment history, survival outcomes, and toxicity profile were obtained retrospectively from medical records. ## Results: A total of 102 patients treated with second-line nab-P/Gem for advanced PDAC after progression on FOLFIRINOX were included. At the time of nab-P/Gem, the median age was 60 years, with males comprising 49.0%, and most (75.5%) had metastatic disease. Patients received a median of three cycles (range 1–12) of nab-P/Gem. The median overall survival (OS) and progre
Who reads Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Heejung Chae; Hyehyun Jeong; Jaekyung Cheon; Hong Jae Chon; Hyewon Ryu; Il-Hwan Kim; Myoung Joo Kang; Jae Ho Jeong; Baek-Yeol Ryoo; Kyu-pyo Kim; Changhoon Yoo
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)